Emergence of acute interstitial pneumonia following high dose interferon delta treatment in a case of chronic myelogenous leukemia.

Abstract

Here we report a 58-year-old man with chronic myelogenous leukemia in the chronic phase, who developed acute respiratory failure following administration of high dose natural interferon delta (6,300 x 10(4) units/week). Radiological and histological findings were consistent with acute interstitial pneumonia (AIP). Although the pathogenesis remains unclear, it is important to watch for the possible development of AIP when employing interferon delta therapy, especially at high doses.

• Authors: M Murata, M Nagai, S Bando, H Dobashi, J Takahara
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 32 Issue 9 Pg. 716-8 (Sep 1993) ISSN: 0918-2918 [Print] Japan
• PMID: 8142676 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Interferon Type I
• Nitrosourea Compounds
• interferon, delta
• Etoposide
• ranimustine

Topics

• Acute Disease
• Antineoplastic Agents (administration & dosage)
• Combined Modality Therapy
• Etoposide (administration & dosage)
• Humans
• Interferon Type I (administration & dosage, adverse effects)
• Leukemia, Myeloid, Chronic-Phase (complications, drug therapy, therapy)
• Lung Diseases, Interstitial (diagnosis, etiology, pathology)
• Male
• Middle Aged
• Nitrosourea Compounds (administration & dosage)
• Pulmonary Alveoli (pathology)